Cyclerion Therapeutics
CYCN
41 hedge funds and large institutions have $11.5M invested in Cyclerion Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 12 closing their positions.
0.25% less ownership
Funds ownership: 2.66% → 2.41% (-0.25%)
18% less funds holding
Funds holding: 50 → 41 (-9)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
55% less capital invested
Capital invested by funds: $25.6M → $11.5M (-$14.1M)
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$110K |
| 2 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$43.4K |
| 3 |
Jane Street
New York
|
+$41.8K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$39.1K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$37.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$862K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$585K |
| 3 |
EP
Eversept Partners
New York
|
-$413K |
| 4 |
D.E. Shaw & Co
New York
|
-$136K |
| 5 |
Two Sigma Advisers
New York
|
-$84.8K |
CYCN Hedge Fund Activity: Q2 2022 in Review
41 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q2 2022, worth a combined $11.5M — down 55% from $25.6M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CYCN and 4 opened new positions — a net loss of 8 holders — while 12 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $110K. The largest seller was Pura Vida Investments, exiting entirely with an estimated $862K sold.
- 41 institutional investors held Cyclerion Therapeutics (CYCN) as of Q2 2022, down from 50 in Q1 2022.
- Funds reported $11.5M of Cyclerion Therapeutics stock for Q2 2022, down 55% quarter-over-quarter.
- 4 funds opened new Cyclerion Therapeutics positions in Q2 2022 and 12 closed out, a net change of -8 holders.
- The largest Cyclerion Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $110K added.
- The largest Cyclerion Therapeutics seller in Q2 2022 was Pura Vida Investments, an estimated $862K sold.
Based on aggregated 13F filings for Q2 2022.